MedTrace Logo

Prevention of Renal and Vascular Endstage Disease Intervention Trial

NCT03073018 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 864

Last updated 2017-03-10

No results posted yet for this study

Summary

The Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) was designed to determine whether intervention with the angiotensin-converting enzyme (ACE) inhibitor fosinopril and/or the hydroxymethylglutaryl coenzyme A reductase inhibitor pravastatin reduced cardiovascular and renal events in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria.

Conditions

Interventions

DRUG

Fosinopril

oral administration, capsules

DRUG

Pravastatin

oral administration, capsules

DRUG

Fosinopril Placebo

oral administration, capsules

DRUG

Pravastatin Placebo

oral administration, capsules

Sponsors & Collaborators

  • Dutch Kidney Foundation

    collaborator OTHER

  • Netherlands Heart Foundation

    collaborator OTHER

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Wiek H van Gilst, PhD · UMCG

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-04-30
Primary Completion
2003-06-30
Completion
2003-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03073018 on ClinicalTrials.gov